Tremfya patent expiry?

There isn’t a single “Tremfya patent expiry.” Tremfya (guselkumab) is covered by multiple patent families (composition of matter, methods of use, manufacturing, formulations, etc.), and expiry dates vary by jurisdiction. In addition to patent terms, the US provides regulatory data exclusivity for biologics.

Key point for the US:
- Even after relevant patents expire, guselkumab is protected by 12 years of regulatory data exclusivity for biologics (BPCIA) from the first approval, which would extend protection against biosimilar competition into roughly 2029 in practice.

Other markets (EU, Japan, etc.) have their own patent term rules and exclusivity periods, which often yield different expiry timelines.

If you want precise expiry dates for a specific country or region (and to the relevant patent families), tell me the jurisdiction and I can pull the current, cited expiry dates from patent databases and regulatory sources. Keep in mind that dates can change due to term adjustments, continuations, and litigation.